TY - JOUR T1 - Safety and Short-term Therapeutic Effects of Miriplatin–Lipiodol Suspension in Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2983 LP - 2988 VL - 31 IS - 9 AU - KAZUTOSHI OKABE AU - TORU BEPPU AU - KATSUKI HARAOKA AU - YOSHIHIRO OH-UCHIDA AU - SADAHIRO YAMAMURA AU - SHINJIRO TOMIYASU AU - TSUYOSHI YAMANAKA AU - OSAMU SANO AU - TOSHIRO MASUDA AU - AKIRA CHIKAMOTO AU - SHIGETOSHI FUJIYAMA AU - HIDEO BABA Y1 - 2011/09/01 UR - http://ar.iiarjournals.org/content/31/9/2983.abstract N2 - Aim: To determine the safety and usefulness of a novel anticancer drug, miriplatin, in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Patients and Methods: Patients (n=115) who underwent TACE with miriplatin–lipiodol suspension (miriplatin group), and control patients (n=131) who underwent TACE with cisplatin–lipiodol suspension (CDDP group) took part in this study. Results: The overall incidence of adverse events was significantly lower in the miriplatin group. The percentage of patients attaining treatment effect 4 in both groups was not significantly different. The proportion exhibiting a >50% decrease in positive tumor markers following TACE was significantly greater in the CDDP group for alpha-fetoprotein, but not significantly different for des-gammma-carboxy prothrombin. Conclusion: Miriplatin–lipiodol suspension was associated with reduced intensity of adverse events and had comparable short-term therapeutic effects to cisplatin–lipiodol suspension, thereby indicating its usefulness in TACE. ER -